The Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial of the National Cancer Institute: history, organization, and status - PubMed (original) (raw)
The Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial of the National Cancer Institute: history, organization, and status
J K Gohagan et al. Control Clin Trials. 2000 Dec.
Abstract
The Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial is enrolling 148,000 men and women ages 55-74 at ten screening centers nationwide with balanced randomization to intervention and control arms. For prostate cancer, men receive a digital rectal examination and a blood test for prostate-specific antigen. For lung cancer, men and women receive a posteroanterior view chest X-ray. For colorectal cancer, men and women undergo a 60-cm flexible sigmoidoscopy. For ovarian cancer, women receive a blood test for the CA125 tumor marker and transvaginal ultrasound. Members of the control arm continue with their usual care. Follow-up in both groups will continue for at least 13 years from randomization to assess health status and cause of death. The primary endpoint is mortality from the four PLCO cancers, which accounts for about 53% of all cancer deaths in men and 41% of cancer deaths in women in the United States each year. Blood specimens are collected from screened participants, buccal cell DNA from controls, and histology slides from cases; these are maintained in a biorepository. Participants complete a baseline questionnaire (covering health status and risk factors) and a dietary questionnaire. More than 12,000 participants were enrolled in the pilot phase (concluded in September 1994). Changes in the eligibility criteria followed. As of April 2000, enrollment exceeded 144,500. Data are scanned into designated on-site computers for uploading by participant identification number to the coordinating center for quality checks, archival storage, and preparation of analysis datasets for use by the National Cancer Institute (NCI). Scientific direction is provided by NCI scientists, trial investigators, external consultants, and an independent data safety and monitoring board. Performance and data quality are monitored via data edits, site visits, random record audits, and teleconferences. The PLCO trial is formally endorsed by the American Cancer Society and has been ranked by the American Urological Association as one of the most important prostate cancer studies being conducted. Special efforts to enroll black participants are cosponsored by the U.S. Centers for Disease Control and Prevention.
Similar articles
- The PLCO Cancer Screening Trial: Background, Goals, Organization, Operations, Results.
Gohagan JK, Prorok PC, Greenwald P, Kramer BS. Gohagan JK, et al. Rev Recent Clin Trials. 2015;10(3):173-80. doi: 10.2174/1574887110666150730123004. Rev Recent Clin Trials. 2015. PMID: 26238115 Review. - Design of the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial.
Prorok PC, Andriole GL, Bresalier RS, Buys SS, Chia D, Crawford ED, Fogel R, Gelmann EP, Gilbert F, Hasson MA, Hayes RB, Johnson CC, Mandel JS, Oberman A, O'Brien B, Oken MM, Rafla S, Reding D, Rutt W, Weissfeld JL, Yokochi L, Gohagan JK; Prostate, Lung, Colorectal and Ovarian Cancer Screening Trial Project Team. Prorok PC, et al. Control Clin Trials. 2000 Dec;21(6 Suppl):273S-309S. doi: 10.1016/s0197-2456(00)00098-2. Control Clin Trials. 2000. PMID: 11189684 Clinical Trial. - Quality control of cancer screening examination procedures in the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial.
Weissfeld JL, Fagerstrom RM, O'Brien B; Prostate, Lung, Colorectal and Ovarian Cancer Screening Trial Project Team. Weissfeld JL, et al. Control Clin Trials. 2000 Dec;21(6 Suppl):390S-399S. doi: 10.1016/s0197-2456(00)00094-5. Control Clin Trials. 2000. PMID: 11189690 - Recruitment strategies in the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial: the first six years.
Simpson NK, Johnson CC, Ogden SL, Gamito E, Trocky N, McGuire C, Martin J, Barrow S, Lamerato L, Flickinger LM, Broski KG, Engelhard D, Hilke C, Bonk J, Gahagan B, Gren LH, Childs J, Lappe K, Fouad M, Thompson J, Sullivan D; Prostate, Lung, Colorectal and Ovarian Cancer Screening Trial Project Team. Simpson NK, et al. Control Clin Trials. 2000 Dec;21(6 Suppl):356S-378S. doi: 10.1016/s0197-2456(00)00102-1. Control Clin Trials. 2000. PMID: 11189688 - Managing Multi-Center Recruitment in the PLCO Cancer Screening Trial.
Gohagan JK, Broski K, Gren LH, Fouad MN, Higgins D, Lappe K, Ogden S, Shambaugh V, Pinsky PF, O'Brien B, Yurgalevich S, Riley T, Wright P, Prorok PC. Gohagan JK, et al. Rev Recent Clin Trials. 2015;10(3):187-93. doi: 10.2174/157488711003150928123938. Rev Recent Clin Trials. 2015. PMID: 26435288 Review.
Cited by
- Preliminary effects of risk-adapted PSA screening for prostate cancer after integrating PRS-specific and age-specific variation.
Liu X, Duan H, Liu S, Zhang Y, Ji Y, Zhang Y, Feng Z, Li J, Liu Y, Gao Y, Wang X, Zhang Q, Yang L, Dai H, Lyu Z, Song F, Song F, Huang Y. Liu X, et al. Front Genet. 2024 Aug 1;15:1387588. doi: 10.3389/fgene.2024.1387588. eCollection 2024. Front Genet. 2024. PMID: 39149591 Free PMC article. - A prospective study of smoking-related white blood cell DNA methylation markers and risk of bladder cancer.
Vermeulen R, Bodinier B, Dagnino S, Wada R, Wang X, Silverman D, Albanes D, Freedman N, Rahman M, Bell D, Chadeau-Hyam M, Rothman N. Vermeulen R, et al. Eur J Epidemiol. 2024 Apr;39(4):393-407. doi: 10.1007/s10654-024-01110-y. Epub 2024 Mar 30. Eur J Epidemiol. 2024. PMID: 38554236 Free PMC article. - Association of exercise with pan-cancer incidence and overall survival.
Lavery JA, Boutros PC, Knight D, Tammela T, Moskowitz CS, Jones LW. Lavery JA, et al. Cancer Cell. 2024 Feb 12;42(2):169-171. doi: 10.1016/j.ccell.2023.12.007. Epub 2024 Jan 4. Cancer Cell. 2024. PMID: 38181796 - Impacts on functional and oncological outcomes of Robotic-assisted Radical Prostatectomy 10 years after the US Preventive Service Taskforce recommendations against PSA screening.
Moschovas MC, Jaber A, Saikali S, Sandri M, Bhat S, Rogers T, Gamal A, Loy D, Patel E, Reddy S, Sighinolfi MC, Rocco B, Harvey T, Ficarra V, Patel V. Moschovas MC, et al. Int Braz J Urol. 2024 Jan-Feb;50(1):65-79. doi: 10.1590/S1677-5538.IBJU.2023.0530. Int Braz J Urol. 2024. PMID: 38166224 Free PMC article. - Contraception as chemoprevention of ovarian cancer in BRCA1 and BRCA2 women.
Loizzi V, Cerbone M, Arezzo F, Silvestris E, Damiani GR, Cazzato G, Cicinelli E, Cormio G. Loizzi V, et al. Hormones (Athens). 2024 Jun;23(2):277-286. doi: 10.1007/s42000-023-00519-6. Epub 2023 Dec 19. Hormones (Athens). 2024. PMID: 38112915 Review.
MeSH terms
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials
Miscellaneous